anti-SARS-CoV-2 cocktail antibodies (Beijing Institutes of Life Science)

N/A

Report date: 2025/01/26 19:31:48

Base Information

Drug Nameanti-SARS-CoV-2 cocktail antibodies (Beijing Institutes of Life Science)
Drug Alias NameB38 and H4 human neutralizing antibodies (Beijing Institute Of Genomics Chinese Academy Of Sciences)spike protein receptor-binding domain specific antibodies (Beijing Institute Of Genomics Chinese Academy Of Sciences)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody
Mechanisms of ActionCoronavirus spike glycoprotein inhibitorsAngiotensin-converting enzyme 2 inhibitors
TargetsAngiotensin-converting enzyme 2Coronavirus spike glycoprotein
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesBeijing Institute Of Genomics, Chinese Academy Of Sciences (National Center For Bioinformatics)
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Institute Of Genomics, Chinese Academy Of Sciences (National Center For Bioinformatics)
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A